• Vardenafil HCl Trihydrate: Precision in PDE5 Inhibition Assa

  2026-06-06

  Vardenafil HCl Trihydrate sets the standard for nanomolar-precision PDE5 inhibition, empowering researchers to dissect cGMP signaling and smooth muscle relaxation with unmatched selectivity. This practical guide spotlights optimized workflows, proteoform-resolved applications, and actionable troubleshooting strategies that drive reproducibility and insight.

• Transferring MoA Prediction with Machine Learning Across Cel

  2026-06-05

  Warchal et al. systematically evaluated machine learning classifiers for predicting compound mechanism of action (MoA) across genetically distinct cancer cell lines using high-content imaging. Their findings reveal that while deep learning and ensemble tree models perform similarly within a cell line, ensemble-based approaches transfer better across cell lines, highlighting key limitations and considerations for cross-line phenotypic screening.

• Dual-Action Kinase Inhibitors Accelerate p38α MAPK Dephospho

  2026-06-05

  This study reveals that certain kinase inhibitors not only block the active site of p38α MAP kinase but also promote its dephosphorylation by phosphatases, introducing a dual-action mechanism. These findings have significant implications for the design of more potent, selective inhibitors in inflammatory and signaling pathway research.

• Shionone Activates Mitophagy to Counter Pulmonary Fibrosis v

  2026-06-04

  This study uncovers that shionone, a terpenoid from Ligularia fischeri, alleviates pulmonary fibrosis by activating mitophagy through the PINK1-Parkin pathway. The research clarifies a mechanism linking mitochondrial quality control and reduced oxidative stress with anti-fibrotic outcomes, suggesting new therapeutic avenues for interstitial lung disease.

• Nelfinavir Mesylate: Bridging HIV Inhibition and Ferroptosis

  2026-06-04

  Explore how Nelfinavir Mesylate, a potent HIV-1 protease inhibitor, is redefining translational research by linking antiviral efficacy with innovative ferroptosis modulation. This article unpacks mechanistic insights, experimental strategies, and the evolving therapeutic landscape, empowering researchers to leverage Nelfinavir Mesylate for both HIV infection studies and emerging cell death paradigms.

• Protocol Use of HyperScribe™ T7 High Yield Cy3 RNA Labeling

  2026-06-03

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus provides a reliable method for synthesizing high-yield, randomly Cy3-labeled RNA probes suitable for fluorescence-based detection in research settings. It addresses technical bottlenecks in RNA probe generation for in situ hybridization and Northern blotting, but is not validated for diagnostic or therapeutic use.

• Revisiting Sumatriptan Metabolism: CYP-Mediated Pathways Unc

  2026-06-03

  This study reevaluates the metabolic fate of sumatriptan, revealing that cytochrome P450 enzymes—specifically CYP1A2, CYP2C19, and CYP2D6—contribute to its N-demethylation, challenging the previous consensus of exclusive MAO A-mediated degradation. These insights refine our understanding of amine drug metabolism and have significant implications for research on neuroactive compounds and their analogs.

• Synergistic Inhibition of Pancreatic EMT via CDK4/6 and BET

  2026-06-02

  Gu et al. demonstrate that combined inhibition of CDK4/6 and BET proteins synergistically suppresses pancreatic ductal adenocarcinoma (PDAC) growth and epithelial-mesenchymal transition (EMT) by modulating the GSK3β-mediated Wnt/β-catenin and TGF-β/Smad signaling axes. This mechanistic insight guides the rational design of combination therapies and highlights the need for precise pathway modulation in preclinical cancer models.

• Reverse Transcription Beyond Limits: Mechanisms, Strategy, a

  2026-06-02

  Gain an advanced perspective on how HyperScript™ Reverse Transcriptase redefines cDNA synthesis for translational research. This article integrates mechanistic insights, strategic workflow guidance, and translational relevance, with evidence from recent ER stress studies and competitive benchmarking. Discover actionable parameters, an honest look at current limitations, and a forward-thinking outlook—distinguishing this resource from conventional product coverage.

• Pioglitazone as a Precision Immunometabolic Probe in Disease

  2026-06-01

  Explore how Pioglitazone, a selective PPARγ agonist, enables advanced immunometabolic research by modulating macrophage polarization, metabolic pathways, and neuroinflammation. This article delivers new insights into experimental design and translational relevance, distinguishing itself from prior reviews.

• Laminin (925-933): Precision Peptide for Cell Migration Assa

  2026-06-01

  Laminin (925-933) distinguishes itself as a functional domain peptide, enabling highly specific and reproducible cell adhesion and migration workflows. By mimicking key regions of the laminin B1 chain, this APExBIO reagent bridges bench research and translational models in oncology, neurobiology, and disease modeling.

• p-tau Ser356 as a Marker and Target in Alzheimer’s Disease P

  2026-05-31

  The referenced study demonstrates that phosphorylation of tau at Ser356 is closely linked with Alzheimer’s pathology and synaptic disruption. Notably, pharmacological inhibition of NUAK1 with WZ4003 selectively reduces p-tau Ser356 in human brain slice cultures, suggesting a potential therapeutic avenue and the need for careful model selection in translational research.

• Murine RNase Inhibitor in Antiviral RNA Research: Mechanisms

  2026-05-30

  Explore how Murine RNase Inhibitor enables precise RNA degradation prevention in advanced molecular biology and antiviral research. Discover its unique oxidative resistance, practical protocol guidance, and implications for next-generation RNA assays.

• LARP1 Directly Binds Ribosomal Subunits to Regulate TOP mRNA

  2026-05-29

  This study elucidates the direct molecular interaction between LARP1 and non-translating ribosomal subunits, resolving long-standing questions about LARP1’s mechanistic role in repressing and stabilizing terminal oligopyrimidine tract (TOP) mRNAs. Through cryo-EM and biochemical methods, it challenges previous models and provides new insight into translational regulation, with practical implications for designing precise protein-RNA interaction experiments.

• XPO1 Inhibition Sensitizes GCB-DLBCL to Platinum Chemotherap

  2026-05-29

  This study demonstrates that selective inhibition of XPO1 (CRM1) via selinexor enhances the efficacy of platinum-based chemotherapy in germinal-center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL) models. Synergistic effects were observed in cell viability reduction and apoptosis induction, supporting the rationale for clinical exploration of XPO1 inhibitor–platinum combinations in refractory DLBCL.

556 records 16/38 page Previous Next First page 上5页 1617181920 下5页 Last page